Inozyme Pharma, Inc. financial data

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 14 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 460% % -67%
Debt-to-equity 94% % 136%
Return On Equity -160% % -172%
Return On Assets -82% % -96%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64,240,198 shares 3.9%
Common Stock, Shares, Outstanding 64,470,243 shares 4.3%
Entity Public Float $199,349,178 USD -0.06%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 64,278,527 shares 4.1%
Weighted Average Number of Shares Outstanding, Diluted 64,278,527 shares 4.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $84,499,000 USD 36%
General and Administrative Expense $20,974,000 USD 7.4%
Operating Income (Loss) $107,373,000 USD -32%
Nonoperating Income (Expense) $657,000 USD -85%
Net Income (Loss) Attributable to Parent $106,716,000 USD -38%
Earnings Per Share, Basic -2 USD/shares -24%
Earnings Per Share, Diluted -2 USD/shares -24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $25,846,000 USD 25%
Cash, Cash Equivalents, and Short-term Investments $84,800,000 USD -49%
Assets, Current $93,637,000 USD -46%
Property, Plant and Equipment, Net $608,000 USD -54%
Operating Lease, Right-of-Use Asset $410,000 USD -59%
Assets $95,164,000 USD -46%
Accounts Payable, Current $3,670,000 USD 69%
Employee-related Liabilities, Current $3,666,000 USD -4.5%
Accrued Liabilities, Current $12,742,000 USD 37%
Liabilities, Current $42,781,000 USD 245%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $63,366,000 USD 9.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $5,000 USD 95%
Retained Earnings (Accumulated Deficit) $415,993,000 USD -35%
Stockholders' Equity Attributable to Parent $31,798,000 USD -73%
Liabilities and Equity $95,164,000 USD -46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $29,149,000 USD -19%
Net Cash Provided by (Used in) Financing Activities $228,000 USD 43%
Net Cash Provided by (Used in) Investing Activities $33,684,000 USD 224%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 64,470,243 shares 4.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $125,347,000 USD 41%
Deferred Tax Assets, Gross $125,501,000 USD 41%
Operating Lease, Liability $669,000 USD 123%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $106,616,000 USD -38%
Lessee, Operating Lease, Liability, to be Paid $684,000 USD -60%
Property, Plant and Equipment, Gross $3,938,000 USD 1.5%
Operating Lease, Liability, Current $669,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year One $944,000 USD -7.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $15,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $52,767,000 USD 23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $300,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $154,000 USD -62%
Share-based Payment Arrangement, Expense $8,111,000 USD 22%
Interest Expense $1,395,000 USD 81%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%